Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bull Exp Biol Med ; 171(4): 480-482, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34542754

RESUMO

We studied the effect of nitinol, the most prevalent material for endovascular stents, on metabolic and coagulation activity of a primary culture of human umbilical vein endothelial cells (HUVEC). Metabolic activity was evaluated using MTS-test and by the level of stable NO metabolites in the conditioned medium, coagulation activity was assessed by activity of von Willebrand factor (vWF) and levels of plasminogen activator inhibitor-1 (PAI-1) and soluble endothelial protein C receptors (sEPCR). Exposure to nitinol reduced metabolic activity of the cell culture by 11.1% in comparison with the control (p<0.001). Although absolute activity of vWF and absolute level of sEPCR were elevated, incubation with nitinol did not lead to a statistically significant elevation of these parameters in comparison with the control, which can indicate the absence of substantial hypercoagulation effects of nitinol.


Assuntos
Ligas/farmacologia , Endotélio Vascular/efeitos dos fármacos , Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos , Coagulação Sanguínea/efeitos dos fármacos , Fatores de Coagulação Sanguínea/metabolismo , Células Cultivadas , Receptor de Proteína C Endotelial/efeitos dos fármacos , Receptor de Proteína C Endotelial/metabolismo , Endotélio Vascular/metabolismo , Endotélio Vascular/fisiologia , Células Endoteliais da Veia Umbilical Humana/metabolismo , Células Endoteliais da Veia Umbilical Humana/fisiologia , Humanos , Inibidor 1 de Ativador de Plasminogênio/efeitos dos fármacos , Inibidor 1 de Ativador de Plasminogênio/metabolismo , Trombose/metabolismo , Trombose/patologia , Fator de von Willebrand/efeitos dos fármacos , Fator de von Willebrand/metabolismo
2.
Angiol Sosud Khir ; 23(4): 69-74, 2017.
Artigo em Russo | MEDLINE | ID: mdl-29240058

RESUMO

The problem of venous thromboembolic complications (VTECs) in patients with cardiovascular implantable electronic devices (CIEDs) is extremely important today because of an annually increasing number of surgical interventions for life-threatening arrhythmias and chronic heart failure. There are hitherto no clearly defined reliable risk factors for VTECs due to heterogeneity of the available literature data. Some sources point to elevated thrombus formation in patients with a large number of electrodes, in repeat operative interventions, in the presence of a temporary pacemaker, in implantation on the left side, silicon cover of an electrode, others refute these facts. Still undetermined remains the choice of antithrombotic therapy for prevention and treatment of VTECs in this cohort of patients. Implantation of a VTEC may be accompanied by thrombosis of deep veins of the upper extremities up to the development of total occlusion of veins. In rare cases, thrombosis extends proximally, there appears superior vena cava syndrome which may require surgical treatment. Diagnosis of these diseases is complicated by their symptom-free course in the majority of cases. The most dangerous VTEC is pulmonary thromboembolism very commonly not accompanied by clinical symptomatology or taking its course under the mask of other more frequent diseases. Despite the fact that pulmonary thromboembolism with a source in the system of the superior vena cava is rarely massive, it may lead to the development of chronic postembolic pulmonary hypertension and to decreased quality of life. The article contains a review of the present-day literature and a clinical case report concerning the development of VTECs in a patient with a CIED in the form of thrombosis of the right internal jugular, subclavian and brachiocephalic veins, pulmonary embolism of small branches of the right pulmonary artery, suppuration of the pacemaker's bed and sepsis. Therapy with antibiotics, low-molecular-weight heparins, antiplatelet drugs and anti-inflammatory agents with regular sanitation of the pacemaker's bed turned out effective.


Assuntos
Antibacterianos/administração & dosagem , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Heparina de Baixo Peso Molecular/administração & dosagem , Veias Jugulares , Marca-Passo Artificial , Implantação de Prótese , Rivaroxabana/administração & dosagem , Veia Subclávia , Infecção da Ferida Cirúrgica , Tromboembolia , Idoso , Anticoagulantes/administração & dosagem , Bloqueio Atrioventricular/cirurgia , Procedimentos Cirúrgicos Cardíacos/métodos , Humanos , Veias Jugulares/diagnóstico por imagem , Veias Jugulares/patologia , Masculino , Implantação de Prótese/efeitos adversos , Implantação de Prótese/métodos , Risco Ajustado , Veia Subclávia/diagnóstico por imagem , Veia Subclávia/patologia , Veia Subclávia/cirurgia , Infecção da Ferida Cirúrgica/diagnóstico , Infecção da Ferida Cirúrgica/tratamento farmacológico , Infecção da Ferida Cirúrgica/fisiopatologia , Tromboembolia/diagnóstico , Tromboembolia/tratamento farmacológico , Tromboembolia/etiologia , Tomografia Computadorizada por Raios X/métodos , Resultado do Tratamento , Ultrassonografia Doppler Dupla/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...